Prometic announces agreement to commercialize prion capture technology

07-Jan-2010 - ProMetic Life Sciences Inc. announced that it has entered into a collaboration agreement with Abraxis BioScience, Inc. to develop and commercialize various applications deriving from ProMetic's prion capture technology platform. As part of the Agreement, Abraxis and ProMetic will equally share ...

Prometic obtains controlling stake in Pathogen Removal and Diagnostic Technologies Inc.

Non Cash Transaction results in ProMetic increasing its holding of common stock from 26% to 77%

08-Oct-2009 - ProMetic Life Sciences Inc. announced that it has finalized its intended transaction with the American Red Cross (ARC) to acquire, in a non-cash transaction, its common stock holding in Pathogen Removal and Diagnostic Technologies Inc. (PRDT). The transaction, originally announced in April ...

ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use

First phase of development of product to reduce risk of variant Creutzfeldt-Jakob Disease from plasma product completed on schedule

25-Jan-2008 - ProMetic Life Sciences Inc. announced that its UK-based subsidiary, ProMetic BioSciences Ltd ("PBL"), has successfully completed the first phases of development utilizing Pathogen Removal and Diagnostic Technologies Inc.'s ("PRDT") ligand technology for prion binding and removal from a plasma ...

ProMetic and Blue Blood of Taiwan form strategic alliance to develop plasma-derived drugs

13-Jun-2007 - ProMetic BioTherapeutics, Inc., a subsidiary of ProMetic Life Sciences Inc. , and Blue Blood Biotech Corporation have formed a strategic alliance to develop drugs derived from human plasma utilizing ProMetic's proprietary manufacturing process. The alliance between the two companies will ...

Kedrion and ProMetic Form Strategic Alliance to Develop Orphan Drugs from Plasma

15-Mar-2007 - Kedrion S.p.A. and ProMetic BioTherapeutics, Inc., a subsidiary of ProMetic Life Sciences Inc. have formed a strategic alliance to develop orphan drugs derived from human plasma utilizing ProMetic's proprietary manufacturing process, the Plasma Protein Purification System (PPPS). The alliance ...

Prometic and Top Meadows establish joint venture for development of Mad Cow Disease diagnostics

13-Jun-2005 - ProMetic Life Sciences Inc. and its UK-based subsidiary, ProMetic BioSciences Ltd announced that they have entered into a Memorandum of Understanding (MOU) with Top Meadow Life Sciences Inc. ("Top Meadow"), a subsidiary of Top Meadow Farms, for the development, marketing and distribution of novel ...

Prometic Finalizes Major Technology Licencing Agreement in Tunisia

20-Dec-2004 - ProMetic Life Sciences Inc. announced the closing of a collaborative agreement with Tunisian partners. ProMetic's Enabling Technology has been licensed to BioMena S.A., a newly-formed private company whose corporate mission will be to manufacture biopharmaceuticals for the treatment of anemia, ...

ProMetic Life Sciences receives Bioseparation Technology Leadership of the Year Award

29-Nov-2004 - ProMetic Life Sciences Inc. has received the Frost & Sullivan 2004 Bioseparation Technology Leadership Award for its sustained technological leadership in the bioseparation sector. This annual award recognizes ProMetic as a pioneer who has steered technological advances in its industry by ...

ProMetic modifies its organiziational structure

27-Sep-2004 - Montreal. ProMetic Life Sciences announced the administrative reorganization of its communications and business development structure. By implementing these changes, the Company is focusing its business development activities in key markets providing optimal growth opportunities namely in the ...

ProMetic Announces Contract with GlaxoSmithKline

08-Jul-2004 - ProMetic Life Sciences Inc. announced that its wholly owned subsidiary ProMetic BioSciences Ltd. has signed a contract with GlaxoSmithKline (GSK) to provide GSK access to ProMetic's unique affinity purification technology. Financial term s were not disclosed. Under the agreement, ProMetic will ...